Literature DB >> 23129549

Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer.

Hiroaki Saito1, Hirohiko Kuroda, Tomoyuki Matsunaga, Tomohiro Osaki, Masahide Ikeguchi.   

Abstract

BACKGROUND: Co-signaling molecules play an important role in T cells. Programmed death-1 (PD-1) is an immunoinhibitory receptor and its overexpression on T cells appears to be involved in immune evasion in cancer patients. The present study was designed to investigate PD-1 expression on T cells and its relationship with immune evasion in gastric cancer patients.
METHODS: PD-1 expression on CD4+ and CD8+ T cells obtained from peripheral blood mononuclear cells (PBMC), normal gastric mucosa, and gastric cancer tissue was evaluated by multicolor flow cytometry.
RESULTS: PD-1 expression on CD4+ and CD8+ T cells from gastric cancer patients was significantly higher than that from normal controls. PD-1 expression on CD4+ and CD8+ T cells was related to disease progression. Furthermore, PD-1 expression on CD4+ and CD8+ T cells from gastric cancer tissue was significantly higher than that from normal gastric mucosa and PBMC. PD-1 positive CD4+ and CD8+ T cells produced significantly less IFN-gamma than PD-1 negative CD4+ and CD8+ T cells.
CONCLUSIONS: Upregulation of PD-1 on both CD4+ and CD8+ T cells may be, in part, responsible for immune evasion in gastric cancer patients.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23129549     DOI: 10.1002/jso.23281

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  44 in total

1.  PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection.

Authors:  Alexander W MacFarlane; Mowafaq Jillab; Elizabeth R Plimack; Gary R Hudes; Robert G Uzzo; Samuel Litwin; Essel Dulaimi; Tahseen Al-Saleem; Kerry S Campbell
Journal:  Cancer Immunol Res       Date:  2013-11-25       Impact factor: 11.151

2.  CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer.

Authors:  Shu Su; Zhengyun Zou; Fangjun Chen; Naiqing Ding; Juan Du; Jie Shao; Lin Li; Yao Fu; Bian Hu; Yang Yang; Huizi Sha; Fanyan Meng; Jia Wei; Xingxu Huang; Baorui Liu
Journal:  Oncoimmunology       Date:  2016-11-22       Impact factor: 8.110

3.  Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer.

Authors:  Y Sunakawa; S Cao; N B Volz; M D Berger; D Yang; A Parekh; W Zhang; S Matsusaka; Y Ning; S Stremitzer; S Stintzing; A Sebio; S Okazaki; T Wakatsuki; M Azuma; M Watanabe; W Koizumi; A H Wu; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2016-05-31       Impact factor: 3.550

Review 4.  Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations.

Authors:  Alexander G Raufi; Samuel J Klempner
Journal:  J Gastrointest Oncol       Date:  2015-10

Review 5.  Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers.

Authors:  Jimmy Hwang
Journal:  J Gastrointest Oncol       Date:  2016-10

6.  PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment.

Authors:  Dimitrios Mathios; Jacob Ruzevick; Christopher M Jackson; Haiying Xu; Sagar R Shah; Janis M Taube; Peter C Burger; Edward F McCarthy; Alfredo Quinones-Hinojosa; Drew M Pardoll; Michael Lim
Journal:  J Neurooncol       Date:  2014-10-28       Impact factor: 4.130

Review 7.  Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma.

Authors:  Manohan Sinnadurai; Kerrie L McDonald
Journal:  J Neurooncol       Date:  2017-03-14       Impact factor: 4.130

Review 8.  Exploring the role of molecular biomarkers as a potential weapon against gastric cancer: A review of the literature.

Authors:  Marwa Matboli; Sarah El-Nakeep; Nourhan Hossam; Alaa Habieb; Ahmed E M Azazy; Ali E Ebrahim; Ziad Nagy; Omar Abdel-Rahman
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

9.  Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection.

Authors:  Shohei Eto; Kozo Yoshikawa; Masaaki Nishi; Jun Higashijima; Takuya Tokunaga; Toshihiro Nakao; Hideya Kashihara; Chie Takasu; Takashi Iwata; Mitsuo Shimada
Journal:  Gastric Cancer       Date:  2015-07-26       Impact factor: 7.370

10.  The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.

Authors:  S Muenst; S D Soysal; F Gao; E C Obermann; D Oertli; W E Gillanders
Journal:  Breast Cancer Res Treat       Date:  2013-06-12       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.